



ELSEVIER
SAUNDERS

Clin Geriatr Med 21 (2005) 793–809

CLINICS IN GERIATRIC MEDICINE

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

- Abandonment, 281
- Abbreviated Injury Scale, 422
- Absorptiometry, dual energy x-ray, 612–613
dual-photon, 612–613
- Abuse, cycle of violence and, 360–361
definition of, by different cultural groups, 360
financial. See *Financial exploitation*.
of elderly. See *Elder abuse*.
- Abusers, criminal liability of, 394–395
domineering, 284
impaired, 284
narcissistic, 284
overwhelmed, 284
recognizing and understanding of,
283–284
sadistic, 284
types of, 284
- Acetaminophen, in arthritis pain, 557
in osteoarthritis, rheumatoid arthritis, and
juvenile chronic arthritis, 552–553
- Acupuncture, in osteoarthritis, 597
- Adult protective services, as community
approach to elder abuse, 431–435
case substantiation by, 433
definitions of, 451
developments in, 452–453
history of, 431–432, 450
interventions by, 433–434
investigations by, 432
myths and misperceptions about,
434–435
need for multidisciplinary
collaborations, 435
patchwork of services throughout
country, 451
state, 389–392
- Advance directives, and designated proxy
decision maker, 201
as planning tools, 241–242
- effectiveness of, 196–197
history of, 194–196
limitations of, 202, 203
proxy decision makers and, 230–231
proxy decisions and, 197–198
proxy interests and, 198
recommendations concerning, 204–205
stability of decisions in, 198–201
tempered interpretation of, 202
use of, evolution of, 201–202
prevalence of, 196
review of literature on, 196–201
written, when not enough, **193–209**
- Aerobic exercise, selection of, 751
- African Americans, end-of-life care and,
239–253
false assumptions of end-of-life care
and, 239
palliative care and, case illustrating,
248–250
synthetic approach to palliative care and,
245–246
- Age, impact on body mass index, 689
treatment for obesity and, 694–695
- Agonist-antagonist, opioid, mixed, 478–479
- Airway obstruction, pathophysiology of,
702–704
- Allopurinol, 502, 585
- Alzheimer's dementia, 261
- Alzheimer's disease, as risk factor for
abuse, 288
nursing home placement in, 289
prognosis in, 316
stages of, 316
- American Pain Society, 94
- Amitriptyline, 480
- Amphetamines, for treatment of obesity, 736
- Anakinra, 519

- Analgesics, nonopioid, 472-474
topical, 483
- Androgens, osteoporosis and, 619
- Anticonvulsants, 482
opioids and, 104
- Antidepressants, 479-480
tricyclic, opioids and, 104-105
- Anti-infective agents, opioids and, 103
- Antimalarials, clinical pharmacology of, 661
efficacy of, 661
history of, 660
mechanism of action of, 660-661
toxicity of, 661-662
- Antirheumatic drugs, disease-modifying, 516,
517-518, 554
use in rheumatoid arthritis, **649-669**
- Anxiolytic agents, 481-482
- Area Agencies on Aging, 444
- Arteritis, giant cell, 632-633
- Arthralgia, drug-induced, 585-586
- Arthritis, crystal-associated, in elderly,
491-511
rheumatoid. See *Rheumatoid arthritis*.
- Arthroplasty(ies), total joint, comorbid conditions influencing, 533-534
in osteoarthritis, 527-528
knee range following, 529
mortality following, risk factors for, 528
nonsurgical medical factors influencing, 533-534
obesity and, 534
outcomes of, health-related quality of life following, 529-530
determinants of, 531-535
pain and function following, determinants of, 528-529
to evaluate, 528
passive motion machine use following, 529
patient outcomes after, **527-541**
patient satisfaction with, 530-531
perioperative surgical complications influencing, 531-532
prosthesis-related factors influencing, 532
psychologic factors influencing, 534-535
- Aspirin, 472-473
- Assessment instruments, **121-146**
broad screening and unfolding approaches in, 123-124
care and services questions in, 136-138
comprehensive, challenges of, 123
domains for, 124, 125
for assessment of competency and communication, 126-128
for assessment of physical function, 128-132
for assessment of psychological function, 132
for assessment of subjective experience in, 138-141
for in-depth/research assessment by domain, 124-139
physical examination and test, 122
question-based, purposes of, 122-123
screening questions as, 121
social and environmental questions in, 132-135
spiritual questions in, 135-136
- Azathioprine, 517

B

- Baclofen, 482
- Balance exercises, 753
- Bariatric beds, 771-772
- Bariatric mattresses, 772
- Bariatric procedures, in obesity, 697, 706
postoperative complications of, 781
- Bariatric programs, in nursing homes,
769-794
admissions and discharge protocols for, 773-774
bathing in, 775
care in, 774
development of, 770
environmental modifications for, 771
equipment for, 771-773
financial implications of, 770-771
for short-term rehabilitation, 774, 783-784
maintenance of dignity and privacy in, 784
medical care in, 780
medical considerations in, 780-781
medications management in, 782
mental health care in, 782
nursing care in, 774-775
nutritional care planning and interventions in, 779-780
nutritional evaluation in, 776-779
physical activity and exercise in, 782-783

- processes and outcomes in,
 monitoring of, 785, 786
quality of care in, 785-786
rehabilitation in, goal of, 783
skin care in, 775
staff safety in, 785
staff training for, 785
transfer and mobility problems in,
 772, 773, 783-784
transportation requirements for, 784
- Bariatrics, 760
- Beds, bariatric, 771-772
- Behavioral clusters, elder abuse and, 337
- Behavioral therapy, in obesity, 720
- Benzodiazepines, opioids and, 104
- Bisphosphonates, osteoporosis and, 617-618
- Body composition, and function, in obese elderly, 682
 studies of, and mobility disability, 681
 functional limitations and, 681
- Body mass index (BMI), as indicator of obesity, 747
 elevated, physical performance testing in, 680-681
 high, calculation of, 776
 functional limitations in, 678-679
 mobility disability in, 678
- Bone, cells of, and proteins in, 603-604
 hormonal regulation of, 604
 composition of, 603
 remodeling process in, 605
 resorption and formation of, 603
 turnover of, methods to approximate, 610
- Bone mass, factors affecting, 606-607
- Breathing, sleep-disordered, 702
 events during, 703
- Bruises, as sign of physical abuse, 342
- Buprenorphine, 479
- Butorphanol, 479
- C**
-
- Calcitonin, bone cells and, 604, 606, 617
 osteoporosis and, 617
- Calcitriol, osteoporosis and, 616
- Calcium, osteoporosis and, 616
- Calcium phosphate (bcp)-hydroxyapatite deposition disease, basic, 506-507
- Calcium pyrophosphate dihydrate crystals, 491
- Calcium pyrophosphate dihydrate deposition disease, 491, 502-506, 520-521
 chondrocalcinosis in, 503, 505
 clinical features of, 504
 diagnosis and differential diagnosis of, 504-506
 management of, 506
 metabolic basis of, 503
- Calorie restriction, and protein liquids, for weight loss, 730
- Canadian Institute of Health Care Research, Palliative Care Research Initiative of, 263
- Cancer patient(s), cognitive impairment in, 96
 delirium in, 110-115
 palliation of symptoms in, 96
 steps in expression of pain in, 95
- Candidiasis, 775
 prevention of, 763
 risk of, in diabetes mellitus, 762-763
- Capsaicin, 483
- Cardiovascular diseases, obstructive sleep apnea and, 708-709
- Cardiovascular risk factors, in obesity, 693
- Caregiver(s), burden faced by, 78-79
 burden of, Zarit Burden Interview to assess, 327, 328
 depression in, 319, 320
 ergonomics and, 765
 family, characteristics of, elder abuse and, 341
 injury of, economic and noneconomic costs of, 761
 lift teams for prevention of, 765
- Caregiver stress theory, 283
- Cataracts, glucocorticoids and, 641
- Centrally acting agents, 474-478
- Cholesterol, orlistat and, 742-743
- Cholinesterase inhibitors, in Alzheimer's disease, 317
- Chondrocalcinosis, in calcium pyrophosphate dihydrate deposition disease, 503, 505
- Churg-Strauss syndrome, 637
- Civil liability, elder abuse and, 394
 of abusers, 394
- Clearinghouse for Abuse and Neglect of the Elderly (CANE), 444
- Clonazepam, 481-482
- Clonidine, 483
- Cockcroft-Gault formula, 471

Code enforcement teams, 441

Codeine, 475

Cognitive decline, dementia and, 339

Cognitive function, obstructive sleep apnea and, 710

Cognitive impairment, pain in, assessment of, 574
 behavioral manifestations of, 573
 symptom assessment in, 96-99

Colchicine, 499, 500, 585, 596-597

Community, approaches to elder abuse in. *See Elder abuse, community approaches to.*

Comprehensive Sexual Assault Assessment Tool (CSAAT), 402-403, 415-425
 revised (CSAAT-E), 420-421, 422, 424

Computed tomography, quantitative, 612-613

Consumer fraud, 368

Continuous positive airway pressure therapy, beneficial effects of, 709
 in sleep apnea, 706, 708, 710

Coronary artery disease, and sleep apnea, mortality in, 708-709

Corticosteroids, in gout, 500

Cost-benefit research, and palliative care, 149-150
 gold standard for, 148-149
 health care resources and, 148
 non-health care resources and, 148
 on health care interventions, 147-148
 quality and quantity of life and, 148-149

Counseling, for healthy obese patients, 750

COX I/COX II agents, 473-474, 595

Creatine kinase, testing of, in statin-associated myopathy, 580

Credit cards, protection of, 376, 377

Criminal liability, elder abuse and, 393-394
 of abusers, 394-395

Cryoglobulinemic vasculitis, 639

Crystal-associated arthritis, **491-511**

Cultural groups, definitions of abuse by, 360

Cultural issues, and elder care, case illustrating, 357-358
 family members return home and, 358-359
 and elder mistreatment, **355-364**

Cycle of violence, 360-361

Cyclobenzaprine, 482-483

Cyclo-oxygenase-2 (COX-2) specific inhibitors (COXIBs), 517

Cyclosporin, 517

Cytokine therapies, clinical pharmacology of, 662-663
 efficacy of, 663
 history of, 662
 mechanism of action of, 662
 toxicity of, 663-664

Cytotoxic therapies, in vasculitis, 642

D

Deaf community, access to care, 362

Death, physician action and, 211-212
 top 10 causes of (1900 and 2000), 76

Decision-making, medical, acceptable to family and health care team, 220
 wants/goals of patients and, 215-217

Decision-making capacity, loss of, deciding for patients in, 228-231

Dehydration, as sign of neglect, 344

Delirium, agitated, pain assessment in, 96-97
 assessment by third party in, 97
 assessment of patients with, 97-98
 causes of, 99
 terminal, pain and, research on, in elderly, **93-119**

Dementia, and cognitive decline, 339
 and depression, 286
 assistance required in, 319
 care in, at home, 318-322
 in nursing homes, 322-324
 elder abuse in, **315-332**
 diagnosis of, 325-326
 treatment, intervention, and prevention of, 326-329
 etiologies of, 315
 Folstein MMSE in assessment of, 98
 medications in, 317
 progression of, losses in, 315-316
 therapies for, 316

Densitometry, single-photon, 612

Depression, dementia and, 286
 weight loss and, 721

Diabetes mellitus, glucocorticoids and, 641
 in obesity, 780

Dicloferac, 597

Dietary management, in obesity, emphasis of, 727
 of obesity, 697
 in elderly, **725-733**

- Dietary restriction, and walking, for weight loss, 730
- Diet(s), healthy, for older adults, 730
for weight-loss program, 717-718
low-carbohydrate, 730
poor, and inactivity, deaths caused by, 761
- Diogenes syndrome, 343-344
- Diuretics, and gout, 497
- Domestic violence legislation, state, 389-392
- Drug absorption, in elderly, 650-651
- Drug distribution, in elderly, 651
- Drug elimination, in elderly, 651-652
- Drug-induced lupus. See *Lupus, drug-induced.*
- Drug metabolism, in elderly, 651
- Drug-related adverse events, 577
- Drug-related errors, morbidity and mortality related to, 577
- Drug therapy, in obesity, 727
- Drugs, analgesic, interaction of, 102-103
causing arthralgias, 585
dosage of, factors affecting, 466-467
management of, in bariatric programs in nursing homes, 782
promoting weight gain, and alternatives, 692
weight-loss, in elderly, trials of, 744
- Durable Power of Attorney for Health Care (DPAHC), 195

E

- Education, in geriatrics and palliative medicine, 11-12
in palliative care, 165-175
- Elder abuse, and neglect, 279-292
and exploitation, policy issues on, 449-457
clues for suspecting, 341-345
in long-term care, 333-354
in nursing homes, 323-324
intervention in, 347-349
legal definitions of, 385-386
legal response to, 386-393
medical implications of, 293-313
patient characteristics and, 339-340
prevention of, 346-347
reporting of, barriers to, 345-346
risk factors for, 338-341
scope of problem of, 337-338
staff risk factors and, 340-341
as complex issue, 451-452
as criminal offense, 363
as offense, 360
background of, 279-280
behavioral clusters and, 337
by family and "friends," 383-384
characteristics of abuser and, 450
commission or omission in, 336
community approaches to, 429-447
adult protective services and, 431-435
case illustrating, 442-443
code enforcement teams in, 441
duty to report in, 430-431
fatality review teams in, 441
interdisciplinary team in, 430, 442-443
medical case management teams in, 435-438, 442-443
victim advocacy organizations, 441-442
context of care and, 336
definition(s) of, 280-281, 334-337, 355
based on interviews of nurses in nursing homes, 335-336
dementia and, 315-332
diagnosis of, in dementia patients, 325-326
domestic, legal and governmental responses to, 383-398
response of federal government to, 387-388
response of state governments to, 388-393
facility characteristics and, 341
failure to report, legal actions in, 393-394
family caregiver characteristics and, 341
forms of, 335, 356
health care professionals and, 302-303
barriers to reporting by, 304-306
health care system use and, 298-299
health care team and, future implications for, 289
identification of, 285-286
ignored, reasons for, 450
in dementia patients, treatment of, intervention, and prevention of, 326-329
in home, 319-320
in inability to communicate, 320
in special populations, 286-289
inattention to, 327
incidence of, 285, 317, 321
intentional or unintentional act and, 336-337
intervention in, as controversial, 329
mortality and, 301-302

- nursing home placement and, 299–301
 - occurrence of, 281–282
 - perception of hurt and, 336
 - perpetrators of, legal actions against, 394–395
 - physical indicators of, 287
 - prevalence of, 384–385
 - preventive approach to, 327
 - quality of life, fear and social isolation and, 296–297
 - functional decline and dependency and, 294
 - self-rated health and helplessness and, 295–296
 - stress and psychologic decline and, 297–298
 - reporters of, 285
 - reporting of, fear of, 361
 - physicians, 294
 - risk factors for, 281–282, 338–341
 - in long-term care, 323
 - screening questions, 286
 - strategies and interventions in, 306–308
 - theories to explain, 318
 - types of, 322
- Elder Justice Act (Senate Bill 333), 454–456
- Elder Law attorney, 370–371, 376
- Elderly, in United States, as fastest growing segment of population, 279, 385
- obese. *See Obesity.*
- pain in, treatment of, 93–94
- palliative care and, 49
- pharmacodynamics in, 650
- pharmacokinetics in, 650
- pharmacologic agents and, 743–744
- physiologic changes in, 650–652
- sexual abuse of, studies of. *See Sexual abuse, of older adults.*
- sleep apnea in, **701–712**
- sleep in, 707–708
- “unbefriended,” 362–363
- weight gain as common in, 748
- weight loss and maintenance in, physician-assisted, **713–723**
- Elderly female, sexual abuse of, forensic markers in, **399–412**
- Emotional abuse, 281
- End of life, consensus on, 226–227
- ethics committees and, 235
- limitation of treatment at, **223–238**
- needs at, screening tool, 140–141
- role of law and legal precedent in, 224–225
- types of treatments for, 227–228
- withdrawing and withholding, as ethically/legally equivalent, 225
- End-of-life care. *See also Palliative care.*
- African Americans and, **239–253**
- agenda for policy improvement, **255–272**
- assumptions about, 240
- coordination of services for, 263
- doctor/patient communication and, 243
- in chronic illness with exacerbations and sudden death, 260–261
- in long dwindling, 261
- in modern era, 1
- in short period of terminal decline, 259
- Medicare and, 262
- methods to achieve reform of, 263–266
- near-term opportunities for reform of, 266
- needs in, systems to support, 262–263
- opioids in, ethical and legal issues in use of, 232–233
- physician training in communication for, 265
- policy changes for reform of, 266
- qualifying for, on basis of need, 258–259
- quality care at, questions to shape research on, 264–265
- research for reform of, 266
- End-of-Life/Palliative Education Resource Center (EPERC), 172
- Energy expenditure, in weight-loss program, 753–754
- Energy requirements, calculation of, in obesity, 778
- Equipment, and furniture for obese patients, 764
- exercise, 752
- for bariatric programs in nursing homes, 771–773
- specialized, to facilitate physical activity, 751
- Ergonomics, caregivers and, 765
- Estrogen replacement, osteoporosis and, 616–617
- Etanercept, 519
- European Organization for Research and Treatment of Cancer (EORTC), 138–139
- Euthanasia, abuse of, 181
- active, 180
- passive, 179
- physician-assisted suicide and, 233–234
- Evidence-based medicine, definition of, 261
- in palliative care, **261**
- Exercise, and physical activity, in bariatric programs in nursing homes, 782–783
- role in weight management and functional improvement, **747–757**

- in weight control, 749
in weight-loss program, 718, 731
types of, for seniors, 751–753
- Exercise equipment, 752
- Exercise programming, for seniors, 749–751
- Exploitation, elder abuse, and neglect, policy issues on, **449–457**
financial. *See Financial exploitation.*
- Extended care facilities. *See Nursing home(s).*
-
- F**
- Fatality review teams, 441
- Fear, and social isolation, quality of life and, 296–297
- Fentanyl, 478
metabolism of, 102–103
routes of administration of, 101–102
- Fiber intake, for older adults, 728
- Financial exploitation, 281, **365–382**
as form of abuse, 359
cases illustrating, 365–366
cognitive impairment as risk factor for, 320
definition of, 367
detection and screening protocol for, 372–373
documentation of, 373–374
evidence of, 368
federal laws concerning, 378–379
follow-up in, 375–380
identification of, 367–369
Internet resources on, 380–381
legal aspects of, 369–372
legal definition of, 386
medical aspects of, 371–372
of older Americans, 395–396
persons perpetrating, 367
prevention of recurrence of, 378
prosecution of, 369, 370
recognition of, difficulty in, 366–367
removal of elder from situation of, 375–380
reporting of, 374–375
state laws concerning, 379–380
- Fitness Arthritis and Seniors Trial (FAST), 683
- Flexibility exercises, 753
- Fluid and nutrition, orally ingested, voluntary refusal of, 231–232
- Fluid intake, for older adults, 728
- Folstein MMSE, in assessment of dementia, 98
- Forensic markers, of sexual abuse of elderly female, **399–412**
- Fractures, as sign of physical abuse, 342
- Fright mail, 395
- Functional Assessment of Chronic Illness Therapy (FACT), 139
- Functional decline, and dependency, quality of life and, 295–296
in relation to body mass index, 680
obesity and, **677–687**
weight loss/weight gain as risk factor for, 679
- Functional impairment, homebound status and, 680
- Functional limitations, obesity-associated, excessive fat mass and, 682
studies of body composition and, 681
- Futile treatment, 211
demands for, “good death” and, 219–220
prevention of requests for, 217–219
- Futility, definition(s) of, 213–215
in evolution, **211–222**
patient-centered, 214–215
and goals of care, 216–217
physiologic, 213
professional integrity-centered, 213
quantitative, 213–214
resource-centered, 214
social consensus, 215
without goals of care, 217
-
- G**
- Gastric bypass surgery, care following, 781
- Gastroesophageal reflux, sleep apnea and, 709–710
- Gay community, violence toward, and exploitation of, 362
- Geriatrics, and palliative medicine, 57–65.
See also Palliative care, geriatric medicine and.
challenges and lessons in, 12–14
clinical practice of, 9–10
comparison between, 8
conceptual framework of, 4
education in, 11–12
historical comparisons of, 7–8
history of, 4
knowledge and research in, 8–9
timelines in, 5–6
- Giant cell arteritis, 632–633

Glucocorticoids, and cataracts, 641
 and diabetes, 641
 and hypertension, 641
 and myopathy, 641-642
 and osteoporosis, 607-608, 641
 and vasculitis, 641

Glucosamine/chondroitin, 595-596

Gout, 491, 492, 521
 acute, management of, 499-500
 clinical features of, 493-494
 diagnosis and differential diagnosis
 of, 497-498
 diuretic use and, 497
 elderly-onset, clinical features of, 494
 epidemiology and pathogenesis of,
 492-493
 female frequency of, 495
 incidence of, 584
 intercritical, 500-501
 management of, 498, 499
 polyarticular, 494-495
 prevalence of, 492
 serum uric acid and, 584
 small-joint finger involvement in,
 495-496
 tophaceous, early atypical, 496-497

H

Health, and helplessness, self-rated, quality of
 life and, 295-296

Health care, at end of life, futile,
 discontinuation of treatment in, 242
 unwanted and unnecessary, 241
 costs of, insurers and, 212
 spiraling, and patient/family
 expectations, 212-213
 goals of, futility without, 217
 patient-centered futility and,
 216-217

Health care facilities, policy changes in, for
 morbid obesity, 765-766

Health care interventions, cost-benefit research
 on, 147-148

Health care professionals, elder abuse and,
 302-306

Health care system, use of, elder abuse and,
 298-299

Health care team, and elder abuse, future
 implications for, 289
 and family, medical decision-making
 and, 220

Health Information Portability Accountability
 Act (HIPAA), 432

Health Utilities Index, 151-152

Henoch-Schönlein purpura, 638

Histamine H₂-antagonists, opioids and, 104

Home environment, modification of, in
 obesity, 764

Hospice care, 76
 costs and benefits of, 147
 Medicare and, 75, 77
 prognostic requirements of, 77

5-HT selective reuptake inhibitors, 479-480

Hyaluronic acid, 596

Hydrocodone, 475

Hydromorphone, 478

Hygiene, poor, signs of, 343-344

Hypertension, glucocorticoids and, 641
 obstructive sleep apnea and, 708
 sibutramine and, 737

Hyperuricemia, chronic, therapy of, 501-502
 epidemiology and pathogenesis of, 492

Hypothyroidism, in obesity, 692

I

Illness(es), chronic, in United States, 76
 Medicare and, 76-77
 worsening and causing death, 76
 patient/family experience of, 18-20
 patterns of, changing, 18
 trajectories of, and organization of care,
 259-262
 frequency of, 261-262

Immobility, skin injury related to, 761-762

Incontinence, in nursing homes, 781

Infection, and vasculitis, 640-641

Intertrigo, 775

J

Jenny Craig, 719

Joint laxity, osteoarthritis and, 592

K

Kevorkian, Jack, 179

Knee, total arthroplasty of, complications
 following, in obesity, 784

L

- LA Weight Loss Centers, 719
- Laboratory evaluation, in obesity, 693-694
- Leflunomide, clinical pharmacology of, 659
 - efficacy of, 659-660
 - history of, 658
 - mechanism of action of, 658-659
 - toxicity of, 660
- Legal guardianship, 434
- Legal intervention teams, 438-441
 - civil justice system and, 440
 - criminal justice system and, 439
 - criminal prosecution teams and, 439-440
 - fiduciary abuse specialist teams, 440-441
- Lidocaine, 483
- Life, quality of, preferred over quantity of life, 240-241
- Life-sustaining treatment, termination of, definition of, 180-181
- Lifestyle change, psychological and educational approaches to, 729
- Lift teams, for prevention of caregiver injury, 765
- Lifts, for bariatric unit, 772
- Long-term care, sites of, 333
- Long-term care facilities, care of obese patients in, 761
 - elder abuse and, 287-288, 323, 333-354
- Lupus, drug-induced, clinical manifestations of, 582-583
 - definition of, 582
 - diagnostic tests in, 583
 - medications associated with, 583
 - treatment of, 584

M

- Macrolides, clearance of opioids and, 103
- Mail fraud, 395
- Malnutrition, symptoms of, 725
- Mandibular advancement devices, in sleep apnea, 706
- Mattresses, bariatric, 772
- McGill Quality of Life Questionnaire - revised (MQOL), 139
- Medicaid, coverage provided by, 262
- Medical assessment, in obese older patients, 689-699
- Medical case management teams, 435-438
 - common diagnoses of, 437-438
 - history of, 436
 - house calls by, 437
 - interventions by, 438
 - work of, 436-438
- Medical neglect, signs of, 343
- Medical Outcomes Study, Short Form Health Survey, 139
- Medicare, chronic illness and, 76-77
 - end-of-life care and, 262
 - hospice care and, 75, 77
- MediCaring, 266-268
 - basic tenets of, 268
- Medications. *See Drugs and specific medications.*
- Medicine, twin efforts to transform, history and lessons learned from, 3-15
- Mental health care, in bariatric programs in nursing homes, 782-783
- Meperidine, 476-477
- Methadone, 477
 - action of, 109
 - for cancer-related pain, 108
 - in palliative care, advantages of, 109
 - metabolism of, 103
 - rotation with morphine, 109-110
- Methotrexate, 517, 633, 642, 652-655
 - clinical pharmacology of, 653-654
 - efficacy of, 654-655
 - history of, 652
 - mechanism of action of, 652, 653
 - side effects of, 655
- Metoclopramide, opioids and, 105
- Milwaukee shoulder-knee syndrome, 507
- Mirtazapine, 481
- Mistreatment of elders. *See Elder abuse.*
- Mobility disability, studies of body composition and, 681
- Monoamine oxidase inhibitors, opioids and, 105
 - sibutramine and, 737
- Monosodium urate crystals, 491
- Morphine, 475-476
 - intraspinous use of, 102

Myopathy(ies), glucocorticoids and, 641-642
related to statins, 578-581

N

National Center of Elder Abuse (NCEA), 280,
285, 366, 387, 444

National Clearinghouse on Abuse in Late
Life, 444

National Crime Victimization Survey (NCVS)
2002, 399, 400, 410

National Elder Abuse Incidence Study
(NEAIS), 280, 282, 429

National Health and Nutrition and Examination
Survey (NHANES), 677-678, 769-770

National Health Care Quality Report, 264

National Heart Lung and Blood Institute,
obesity guidelines of, 735

National Institutes of Health, obesity
guidelines of, 735

National Policy Summit on Elder Abuse,
453-454

Native American community, protection of
elders by, 363

Natural Death Act (1976), 194-195

Nefazodone, 481

Neglect, 281. See also *Elder abuse*,
and *neglect*.
legal definition of, 386

Nonsteroidal anti-inflammatory drugs
(NSAIDs), 473, 499-500, 501, 516,
594-595
in osteoarthritis, rheumatoid arthritis, and
juvenile chronic arthritis, 552-553
in rheumatic diseases, 557

Nursing home(s), and community settings,
324-325
background checks for employees of,
349-350
bariatric programs in. See *Bariatric
programs, in nursing homes*.
care in obesity, 769
care provided by, 544
goals of, 544
dealing with rheumatic pain in, **543-561**
dementia in, care in, 322-324
incontinence in, 781
interviews of nurses in, definitions of
elder abuse and, 335-336
mistreatment in, 288
patient neglect in, 323-324

Pioneer Network model of care and, 289
placement in, elder abuse and, 299-301
predictors of, 322
pressure ulcers in residents of, 324
residents of, as vulnerable, 322-323
characteristics of, 288
victims of sexual abuse in, 408

Nutrient deficiencies, in obesity, 779-780

Nutrient requirements, obesity management
and, 727-728

Nutritional care, planning and interventions in,
in bariatric programs in nursing homes,
779-780

Nutritional evaluation, in bariatric programs in
nursing homes, 776-779

O

Obese older patients. See *Obesity*.

Obesity, adverse effects of, 769
and aging population, 760-761
and functional decline, **677-687**
and overweight, incidence of, 735
as epidemic in United States, 747-749
assessment of, 690
and management in, 690
attaining "ideal" body weight and,
695-696
behavioral therapy in, 720
burden of, 684
cardiovascular risk factors in, 693
clinician management of, educational
materials for, 698
definition of, 759, 776
dietary management in, 697
functional limitations in, self-reported,
677-680
health risks associated with, 748
homebound status in, 680
impact on function, 684
in elderly, 713-714
and mortality, 714, 726
body composition and function
in, 682
dietary management of, **725-733**
health consequences of, 726
promotion of patient safety and
prevention of caregiver injury
in, **759-767**
intervention studies in, 682-684
laboratory evaluation in, 693-694
medical assessment in, **689-699**
medical history taking in, 691
modification of home environment
in, 764

- morbid, definition of, 776
 health care facilities policy changes for, 765-766
motivation for weight loss in, 691
nursing home care in, 769
osteoarthritis in, 781, 784
pharmacotherapy in, 697
physical examination in, 693
physician intervention in, barriers to, 715
 in development of weight management program, 717
 lack of, 714-715
 to assess obesity risk, 716
 to assess readiness to change, 716-717
 to establish appropriate interventions, 717-721
 to provide follow-up care, 720
prevalence of, 677, 678, 689, 760-761
prevention of, in overweight adults, 755
respiratory problems in, 781
risk factors exacerbating, 761
risk for pressure ulcers in, 762
sleep apnea and, 701
social history taking in, 691
stress incontinence in, 781
total joint arthroplasty and, 534
treatment of, 749
 age and, 694-695
 available, 697-698
 classification of, 695-696
 contraindications to, 696-697
 nutrient requirements and, 727-728
 pharmacologic agents for, **735-746**
 surgical, 697-698
 versus overweight, classification of, 747, 748
- Older adults. *See Elderly.*
- Opiates, 475-478
- Opioid analgesics, starting doses for, 555
- Opioid receptors, 100-101
- Opioids, 475-478
 and opioid receptors, mechanism of action of, 99-101
 anticonvulsive drugs and, 104
 anti-infective agents and, 103
 benzodiazepines and, 104
 clearance of, macrolides and, 103
 drug interactions with, 102-105
 histamine H₂-antagonists and, 104
 intraspinal, 102
 metoclopramide and, 105
 monoamine oxidase inhibitors and, 105
 naturally occurring, 99
 pharmacology of, 99-102
 phenothiazines and, 105
 proton pump inhibitors and, 104
 rotation of, 105-106
 routes of administration of, 101-102
 selective serotonin reuptake inhibitors and, 105
 semisynthetic, 99
 side effects of, 106-108
 St. John's Wort and, 105
 synthetic, 99
 tolerance of, mechanisms of, 101
 tricyclic antidepressants and, 104-105
- Oppiophobia, 475
- Orlistat, and sibutramine, efficacy trials
 comparing, 740-741
 cholesterol and, 742-743
 contraindications to use of, 738
 efficacy trials of, 739-742
 for weight reduction, 735, 737-738
 gastrointestinal effects of, 738
 mechanism of action of, 737
 patient information for use of, 744
 vitamin absorption and, 738
- Osteoarthritis, 522
 biomarkers for, 594
 biomechanical factors in, 592
 chondrocyte biology and, 591
 epidemiology of, 590
 genetic contributions to, 591-592
 in obesity, 781, 784
 incidence of, 543
 joint laxity and, 592
 new developments in, **589-601**
 pain in, algorithm for management of, 548-549
 pathogenesis of, 590-593
 radiography in, 593-594
 synovial inflammation and, 592-593
 total joint arthroplasty in, 527-528
 treatment of, 594-598
 pharmacologic, 589, 594-595
- Osteoblasts, 603, 606
- Osteoclasts, 603, 604, 606
- Osteoporosis, **603-629**
 androgens and, 619
 biphosphonates and, 617-618
 bone loss in, 605
 calcitonin therapy and, 617
 calcium, vitamin D, and calcitriol and, 616
 clinical manifestations of, 609
 diagnosis of, 613-614
 differential diagnosis of, 608-609
 estrogen replacement and, 616-617
 fracture-related, 609
 glucocorticoids and, 641
 laboratory and radiologic features of, 609-611

management of, 614-615
 measurements of skeletal mass and,
 612-613
 pathophysiology of, 605-608
 sodium fluoride and, 618
 strontium ranelate and, 619-620

Overeaters Anonymus, 718

Overweight, and obesity, incidence of, 735
 definition of, 759, 776
 versus obesity, classification of, 747, 748

Oxycodone, 476

P

Pain, acute, 467-468
 treatment of, traditional versus
 modern, 469
 assessment of, and management of, in
 palliative care, 166
 and symptoms of, 94-96
 barriers to, in elderly, 565-567
 functional status and, 570-571
 history in, 568-570
 in agitated delirium, 96-97
 in elderly, 546-547
 physical examination in, 570
 psychologic and social, 571
 care in, areas for improvement of, 558
 chronic, 468, 471
 assessment of, 567-574
 and effective pain
 management, 563-564
 in rheumatic diseases,
 563-576
 definition of, 564
 classification of, 94
 consequences of, 563
 creation of comprehensive pain history
 in, 466
 definitions of, 564
 detection of, roadblocks to, 465
 epidemiology of, 465, 484
 etiologies of, 465
 expression of, in cancer patients, steps
 in, 95
 genetic component of, 100
 history taking in, 487
 in cognitively impaired, assessment
 of, 574
 behavioral manifestations of, 573
 in elderly, management of, 99-110
 nonpharmacologic approaches
 to, 110
 treatment of, 93-94
 in osteoarthritis, algorithm for
 management of, 548-549
 in rheumatoid arthritis, algorithm for
 management of, 550-551

intensity of, measurement of, and pain
 assessment scales, 571-574
 management of, by trained health
 professionals, 243-244
 medication history in, 466
 musculoskeletal, descriptors of, 472
 neuropathic, descriptors of, 472
 nonpharmacologic approaches to,
 547-548
 Numeric Rating Scale and, 546, 547
 patient-related behaviors in, 466,
 485-486
 perception of, in elderly, 545-546
 treatment, and management of, in
 elderly, 465-490
 persistent, common misconceptions on,
 466, 486
 consequences of, 469
 development of, 465, 484
 management of, 484
 recognition of, 466, 486
 setting health care professional
 barriers in, 466, 486-497
 pharmacologic options in, 549-558
 pharmacotherapeutic plan in, 470
 psychosocial and somatic aspects
 of, 468
 relief of, hastening death, acceptance
 of, 182
 rheumatic, assessment of, 545
 dealing with, in extended care
 facilities, 543-561
 incidence of, 543
 increasing with increasing
 age, 544
 unrecognized and untreated,
 543-544
 signs and symptoms of, 466, 485
 treatment guidelines for, of American
 Medical Directors Association,
 544-545
 Verbal Descriptor Scale and, 546

Pain and Palliation Research Group, St. Olavs
 University Hospital, 89-90

Pain assessment instruments, 572

Pain assessment scales, measurement of
 intensity of pain and, 571-574

Pain interview, sample questions in, 569

Palliative care, African Americans and, case
 illustrating, 248-250
 as public health issue, 46-51
 assessment instruments in. *See Assessment
 instruments.*
 barriers to capacity and assent to, 247
 changes in population and, 46, 47
 communication skills, ethics, and law in,
 166, 169-170

- cost-benefit studies of, family medical costs and benefits and, 159
 - family nonmedical costs and benefits and, 159-160
 - patient medical benefits and, 157-158
 - patient medical costs and, 156-157
 - patient nonmedical benefits and, 158-159
- cost-effective solutions to, 51-52
- costs and benefits of, classification of, 149, 150
 - measurement of, 151-156
- description/definition of, 20-22
- disadvantaged groups and, 50-51
- economic deprivation and, 48-49
- education and research in, 79-80
- education in, 165-175
- educational assessment in, 168-169
- educational resources for, 172
- effects of, on patient medical costs, 150-151
- elderly and, 49
- ethical, legal, and policy issues in, 177-178
- ethnic and minority groups and, 49-50
- evidence-based medicine in, 261
- experiential education and faculty development in, 171-172
- foundational concepts for, 27
- geriatric medicine and, 57-65
 - challenges and lessons in, 12-14
 - clinical practice of, 9-10
 - comparison between, 8
 - conceptual framework of, 4
 - education in, 11-12
 - historical comparisons of, 7-8
 - history of, 4
 - in developing countries, 58-59
 - acceptability of, 71
 - access issues in, 72-73
 - accessibility and, 69-70
 - action groups for, 74
 - affordability and, 70-71
 - availability and, 69
 - drug availability and, 75
 - economic factors and, 59, 60
 - elders as caregivers in, 66-67
 - elders as patients in, 67-69
 - ethical issues and, 71-72
 - guidance for starting programs in, 62-65
 - health of elderly and, 60-61
 - HIV/AIDS and, 65, 66
 - policy issues in, 73-74
 - public health aspects of, 60-61
 - setting up services for, 62, 64
 - statistics on, 65-66
 - status of elderly and health, 61-62
- knowledge and research in, 8-9
- guiding principles of, 29
- health care interventions and, 149-150
- health systems and, 167, 171
- in developing countries, for elderly, diverse modes of, 72
 - for young people, 72
- international aspects of, in elderly, 57-78
- learning formats in, 168
- learning objectives in, 168
- models, standards, and guidelines for, 17-44
- needs assessment in, 167-168
- negotiation of patient goals in, 170
- nonpain symptom assessment and management in, 166
- organizational model for, steps to develop value of, 24-33
 - value of, 24, 28
- organizations providing, challenges for, 23-24
- pain and symptom education in, 169
- pain assessment and management in, 166
- price of, 147-163
- psychosocial care in, 167, 170
- public health and, 45-55
- research in, agenda of, 85-86
 - building up of, 81-92
 - collaboration of groups for, 86-87
 - ethical challenges and, 84
 - funding for, 87-88
 - in Norway, external evaluation of, 90
 - interdisciplinary, 88
 - justification for, 84-87
 - leadership for, 87
 - obstacles to, 83-84
 - promotion of, 82
 - quest for, 83
- resources concerning, 34, 40
- service delivery models of, 22-23
- synthetic approach to, Africans
 - Americans and, 245-246
- unmet need and suffering and, 46-48
- WHO definition of, 70
- Palliative care programs, 77-78
- Palliative Care Research Initiative, of Canadian Institute of Health Care Research, 83
- Palliative medicine/hospice/end-of-life care, timelines in, 6-7
- Palliative sedation, 234-235
- Parathyroid hormone, bone cell function and, 604, 618-619
- Patient(s), costs and benefits of palliative care to, cost-benefit studies of, 156-159
 - measurement of, 151-153

- family of, and health care team, medical decision-making and, 220
 - costs and benefits of palliative care to, 159-160
 - medical costs to, effects of palliative care on, 150-151
 - nonmedical costs and benefits of, 153-154
 - wants/goals of, medical decision-making and, 215-217
 - Patient Self-Determination Act (PSDA), 195
 - Pentazocine, 478-479
 - Pharmacodynamics, in elderly, 652
 - Pharmacokinetics, and pharmacologic activity, 471
 - in elderly, 652
 - Pharmacotherapy, and older adults, 743-744
 - for treatment of obesity, **735-746**
 - in obesity, 697
 - in sleep apnea, 706
 - Phenothiazines, opioids and, 105
 - Phentermine, adverse effects of, 736
 - and other drugs, effects of, 736
 - efficacy trials of, 738
 - for treatment of obesity, 736
 - Physical abuse, 280
 - legal definition of, 385-386
 - Physical activity, and exercise, in bariatric programs in nursing homes, 782-783
 - role in weight management and functional improvement, **747-757**
 - current level of, and exercise recommendations, 691
 - daily, role of, 753-754
 - for weight change, 730
 - moderate-intensity, examples of, 754
 - specialized equipment for facilitate, 751
 - Physical examination, in obesity, 693
 - Physical performance testing, in elevated body mass index, 680-681
 - Physical restraints, in Alzheimer's disease, 317
 - Physician(s), action of, death and, 211-212
 - definitions of futility and, 213-215
 - duties of, at end of life, 186
 - reporting of elder abuse by, 294
 - suspicion of motives of, 212
 - Physician-assisted suicide. See *Suicide, physician-assisted*.
 - Physician-assisted weight loss and maintenance, in elderly, **713-723**
 - POLST form, 195
 - Polyangiitis, microscopic, 636-637
 - Polyarteritis nodosa, 633-634
 - Polymyalgia rheumatica, 550, 633
 - Polysomnography, in sleep apnea, 705-706
 - Powers of Attorney documents, checking on, 376-377
 - Pressure ulcers, as sign of neglect, 344-345
 - causes of, 762
 - in obesity, 762, 775-776
 - in residents of nursing homes, 324
 - staging of, 762
 - Project on Death in America (PDIA), 82
 - Proposed Elder Justice Act of 2003, 388
 - Propoxyphene, 477-478
 - in rheumatic pain, 558
 - Protein liquids, and calorie restriction, for weight loss, 730
 - Protein requirements, calculation of, in obesity, 778-779
 - in elderly, 727
 - Proton pump inhibitors, opioids and, 104
 - Proxy decisions, advance directives and, 197-198
 - Proxy interests, advance directives and, 198
 - Pseudogout, 491, 502-506, 520-521
 - Public health, traditional, roots of, 45-46
 - Pulmonary function, weight loss and, 729
-
- Q**
- Quality-adjusted life years (QALY), 149
 - and Health Utilities Index, 151-152
 - benefits of palliative care for family and, 155
 - to measure patient medical costs and benefits, 151-153
 - Quality of life. See *Elder abuse, quality of life*.
 - Quill, Timothy E., 179
-
- R**
- Raloxifene, 617
 - Rape, prevalence estimates of, 400-401
 - Research Network of European Association for Palliative Care (EAPC), 82
 - Respiratory events, sleep-disordered, definitions associated with, 702, 703

- Respiratory problems, in obesity, 781
- Rheumatic diseases, disorders included in, 543
 in elderly, assessing chronic pain in, 563-576
 dealing with rheumatic pain in, 543-561
 rheumatoid arthritis, 513-525
- Rheumatic disorders, drug-related adverse events masquerading as, 577
- Rheumatic pain. *See Pain, rheumatic.*
- Rheumatic syndromes, iatrogenic, in elderly, 577-588
- Rheumatoid arthritis, 513-525
 clinical presentations of, 514
 diagnosis of, 513-514, 515
 differential diagnosis of, 516, 520-522
 disease-modifying antirheumatic drugs in, 649-669
 elderly onset, 514, 515
 etiology and pathogenesis of, 514-515
 morbidity and mortality associated with, 649
 pain in, algorithm for management of, 550-551
 prognosis in, 515-516
 therapy of, 516-520
-
- S**
- Saunders, Cicely, 69, 83
- Scleroderma, drug-induced, 586
- Sedation, palliative, 234-235
- Selective serotonin reuptake inhibitors, opioids and, 105
- Self-neglect, 281, 282-283
 legal definition of, 386
 risk factors for, 283
- Senior Citizens Against Marketing Scams Act (SCAMS), 396
- Sexual abuse, 280
 background of, 414-415
 case study of, 418-419
 criminal justice process and outcomes in, 406-407
 of elderly, core data elements tracking, 413-427
 incidence of, 414
 study in, 415-416
 conceptual framework of, 416-419
 crime and case disposition core elements, 424-425
 offender core elements and, 423-424
 victim care elements and, 419-423
 of elderly females, forensic markers in, 399-412
 of older adults, studies of, 401-402
 compared, 409-410
 methods of, 402-403
 results of, 403-406
 offender in, characteristics of, 423
 and patterns of behavior in, 405-406
 prosecution of cases of, forensic markers and, 407-408
 under-reporting of, 399
 victims of, forensic examination of, 405
 in community-based care, 408
 in nursing homes, 408
 mechanisms of injury to, 403-404
 patterns of injury to, 404, 405
- Sexual assault, signs of, 343
- Sexual Assault Nurse Examiner (SANE), 402, 410, 416
- Sibutramine, adverse effects of, 737
 and orlistat, efficacy trials comparing, 740-741
 contraindications to, 737
 efficacy trials of, 738-739
 for weight loss, 735, 736-737
 MAOIs and, 737
 metabolites of, 736
- Skeletal mass, measurements of, osteoporosis and, 612-613
- Skeletal muscle relaxants, 482-483
- Skin care, in bariatric programs in nursing homes, 775
 in urinary incontinence, 763
- Skin injury, immobility-related, 761-762
- Sleep, in elderly, 707-708
- Sleep apnea, and coronary artery disease, mortality in, 708-709
 gastroesophageal reflux and, 709-710
 in elderly, 701-712
 obesity and, 701
 obstructive, and cardiovascular diseases, 708-709
 clinical presentation of, 704
 cognitive function and, 710
 diagnosis of, 705-706
 hypertension and, 708
 physical examination findings in, 704-705
 prevalence of, 701-702
 polysomnography in, 705-706

- surgery in, 706-707
symptoms of, 704
treatment of, 706-707
- Sleep architecture, changes in, in aging, 707
- Sleep-disordered breathing, 702
events during, 703
- Sleep-disordered respiratory events, definitions associated with, 702, 703
- Sleep Heart Health study, 708
- Sleep history, in obesity, 692-693
- Sleep-promoting agents, 483
- Social isolation, as sign of neglect, 345
- Social Security number, protection of, 376, 377
- Sodium fluoride, osteoporosis and, 618
- St. Christopher's Hospice, 83
- St. John's Wort, opioids and, 105
- Statins, myopathic syndromes related to, 578
management of, 580-581
pathogenesis of, 579-580
risk factors associated with, 578-579
pharmacology of, 579
prescription of, recommendations for, 581
- Strengthening or resistance exercises, 752
- Stress, and psychologic decline, quality of life and, 297-298
- Stress incontinence, in obesity, 780-781
- Strontium ranelate, osteoporosis and, 619-620
- Suicide, physician-assisted, **179-192**
and euthanasia, 233-234
arguments against, 185-187
arguments in favor of, 183-185
as means of expressing autonomy, 244
concerns of patients requesting, 187
debate concerning, 179
definition of, 181
legal changes and, 179-180
steps to reduce perceived need for, 187
- Sulfasalazine, efficacy of, 657-658
history of, 655-656
mechanism of action of, 656-657
structure of, 656
toxicity of, 657
- Surrogate decision making, standard of evidence for, 231
- Synovial inflammation, osteoarthritis and, 592-593
- Systemic lupus erythematosus, 582
-
- ## T
-
- Take Off Pounds Sensibly (TOPS), 719
- Telemarketing fraud, 395
- "Terminal sedation," 182-183, 184
- Tight skin syndromes, drug-induced, 586
- Tizanidine, 483
- Topiramate, 482
- Tracheostomy, in sleep apnea, 706
- Tramadol, 474-475
- Transfer equipment, for bariatric unit, 772
- Treatment, futile. See *Futile treatment*, withdrawal of, 212
- Trial of Non-pharmacologic Interventions in Elderly (TONE), 682-683
- Tricyclic antidepressants, 480-481
-
- ## U
-
- United States Congress House Select Committee of Aging, 384-385
- United States Panel on Cost-Effectiveness, guidelines of, 148-149
- Uric acid, serum, drugs increasing, 584
- Urinary incontinence, skin care in, 763
- Uvulopalatopharyngoplasty, in sleep apnea, 706
-
- ## V
-
- Values, and thoughts, changes in, in brain injury or disease, 193-194
- Vasculitis(ides), cryoglobulinemic, 639
cytotoxic therapies in, 642
drug-induced, 586
glucocorticoids in, 641
in geriatric population, **631-647**
in patients over age 65, 631-639
infection and, 640-641
isolated cutaneous, 637-638
large vessel, 632-633
management considerations in, 639-643
medication interactions in, 642-643
medium vessel, 633

- primary, 631-638
 - secondary, 638-639
 - small vessel, 634-638
- Venlafaxine, 480-481
- Victim advocacy organizations, 441-442
- Visual analog scale (VAS), in pain assessment, 97
- Vitamin B₁₂, for older adults, 728
- Vitamin D, for older adults, 728
- osteoporosis and, 616
- Vitamins, absorption of, orlistat and, 738
- W**
-
- Waist circumference, measurement of, in prediction of mortality, 776-777
- Walking, and dietary restriction, for weight loss, 730
- Wegener's granulomatosis, 635-636
- Weight-bearing exercise, 752
- Weight control, exercise in, 749
- Weight gain, as common in older adults, 748
- causes of, 726
- Weight loss, and maintenance, physician-assisted, in elderly, **713-723**
- barriers to success of, 720-721
 - depression and, 721
 - dietary restriction and walking for, 730
 - in elderly, considerations for, 726-727
 - options for, 729-730
 - in treatment of sleep apnea, 706
 - motivation for, in obesity, 691
 - protein liquids and caloric restriction for, 730
 - recommendations for, 744
 - social support for, 720-721
 - sustained reinforcement for, 720
- Weight-loss drugs, in elderly, trials of, 744
- Weight-loss program(s), as big business, 730
- commercial, 718-720
 - energy expenditure in, 753-754
 - exercise in, 718, 731
 - healthy diet for, 717-718
 - "lifestyle activity" in, 753
 - monitoring in, 696
 - recommendations for, 731
- Weight loss treatment, patient readiness for, evaluation of, 691
- Weight management program, development of, physician intervention in, 717
- Weight reduction, intervention studies in, 682-684
- strategies for, 728-729
- Weight Watchers, 719
- Women's shelters, 444
- World Health Organization (WHO), Aging and Health program of, 65
- definition of palliative care, 70
- Wound care, in obesity, 776